Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 8 Weeks in Subjects With Chronic Genotype 1 HCV and HIV-1 Co-infection

Inclusion Criteria: * Chronic HCV GT1, treatment-naïve, non-cirrhotic adult subjects. * HCV RNA levels more than 10,000 IU/mL and less than 6,000,000 IU/mL at Screening Exclusion Criteria: * Gastrointestinal disorder or post-operative condition that could interfere with the absorption of the study drug. * Solid organ transplantation. * Significant cardiac disease or other significant co-morbidities that could interfere with study treatment. * Malignancy within the 3 years prior to screening, with the exception of specific cancers that have been cured by surgical resection (basal cell skin cancer, etc.). Subjects under evaluation for possible malignancy are not eligible. * Infection with hepatitis B virus (HBV)